Macrocyclic Compounds, SRC MET Inhibitor, Cancer Treatment
Summary
USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.
“The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.”
What changed
USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. covering macrocyclic compounds that inhibit SRC and MET and/or CSF1R, along with pharmaceutical compositions and methods of using such compounds to treat cancer. The patent contains 9 claims.
Affected parties in the pharmaceutical and biotech sectors developing oncology therapeutics should review this grant for freedom-to-operate considerations. The patent may create licensing or design-around obligations for parties working in the SRC/MET/CSF1R inhibitor space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Macrocyclic compounds and uses thereof
Grant US12606571B2 Kind: B2 Apr 21, 2026
Assignee
Turning Point Therapeutics, Inc.
Inventors
Jingrong Jean Cui, Evan W. Rogers, Jane Ung, Jeffrey Whitten, Dayong Zhai, Wei Deng, Xin Zhang, Zhongdong Huang, Jing Liu, Han Zhang
Abstract
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.
CPC Classifications
C07D 498/16 C07K 16/2863 A61P 35/00 A61K 45/06
Filing Date
2024-04-09
Application No.
18630760
Claims
9
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.